Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine
- PMID: 2895828
- DOI: 10.1016/s0140-6736(88)91711-4
Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine
Abstract
The 1986-87 outbreak of paralytic poliomyelitis in Senegal, with 676 reported cases, provided an opportunity to evaluate the efficacy of an enhanced-potency inactivated poliovirus vaccine (N-IPV) in the Kolda region, where this vaccine has been used since 1980. 89 cases, confirmed to have poliomyelitis with residual paralysis, were enrolled in a case-control study, up to 5 matched controls being obtained for each case. The clinical efficacy for one dose of N-IPV was 36% (95% confidence interval 0%, 67%) and for two doses was 89% (95% CI 62%, 97%).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
